Importance of Early Blood Sampling on Vecuronium Pharmacokinetic and Pharmacodynamic Parameters

Clinical Pharmacokinetics

Volumn 24, Issue 6, 1993, Pages 507-518

  Ducharme, Julie ^a,b   Varin, France ^a,b   Bevan, David R ^a,b   Donati, François ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT; VECURONIUM;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; FEMALE; HUMAN; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; VECURONIUM BROMIDE;

EID: 0027264115     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199324060-00006     Document Type: Article

References (34)

1. Monitoring of neuromuscular function
2. Vecuronium in alcoholic liver disease: a pharmacokinetic and pharmacodynamic analysis
3. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure
4. Pharmacokinetics: philosophy of modeling
5. Kinetics of binding of [3H]-acetylcholine to Torpedo post-synaptic membranes: association and dissociation rate constants by rapid mixing and ultrafiltration
6. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Parts I and II)
7. Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate
8. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) and pancuronium in anesthetized humans
9. Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration
10. Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples
11. Electrochemical detection of vecuronium and its metabolites by high performance liquid chromatography
12. Pharmacokinetics of ORG NC 45 (NORCURON) in patients with and without renal failure
13. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model
14. Pharmacokinetics
15. Pharmacokinetic and pharmacodynamic factors that govern the clinical use of muscle relaxants
16. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models
17. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis
18. Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis
19. Distribution, elimination, and action of vecuronium in the elderly
20. The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure
21. Pharmacology of vecuronium in patients with end-stage renal failure
22. Artery-to-muscle onset time for neuromuscular blocking drugs
23. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults
24. The emergence of Org NC 45 from the pancuronium series
25. Estimating the dimension of a model
26. Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats
27. A comparison of parametric with semiparametric analysis of the concentration versus effect relationship of metocurine in dogs and pigs
28. Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anaesthesia
29. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine
30. Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients
31. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
32. Pharmacokinetics and pharmacodynamics of Org NC 45 in man
33. Pharmacokinetics from a dynamical systems point of view
34. Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations